203 related articles for article (PubMed ID: 8377003)
1. Striatal L-dopa decarboxylase activity in Parkinson's disease in vivo: implications for the regulation of dopamine synthesis.
Gjedde A; Léger GC; Cumming P; Yasuhara Y; Evans AC; Guttman M; Kuwabara H
J Neurochem; 1993 Oct; 61(4):1538-41. PubMed ID: 8377003
[TBL] [Abstract][Full Text] [Related]
2. Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease.
Kuwabara H; Cumming P; Yasuhara Y; Léger GC; Guttman M; Diksic M; Evans AC; Gjedde A
J Nucl Med; 1995 Jul; 36(7):1226-31. PubMed ID: 7790948
[TBL] [Abstract][Full Text] [Related]
3. Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms.
Cumming P; Gjedde A
Synapse; 1998 May; 29(1):37-61. PubMed ID: 9552174
[TBL] [Abstract][Full Text] [Related]
4. Human striatal L-dopa decarboxylase activity estimated in vivo using 6-[18F]fluoro-dopa and positron emission tomography: error analysis and application to normal subjects.
Kuwabara H; Cumming P; Reith J; Léger G; Diksic M; Evans AC; Gjedde A
J Cereb Blood Flow Metab; 1993 Jan; 13(1):43-56. PubMed ID: 8417009
[TBL] [Abstract][Full Text] [Related]
5. Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism.
Melamed E; Hefti F; Wurtman RJ
Ann Neurol; 1980 Dec; 8(6):558-63. PubMed ID: 6260009
[TBL] [Abstract][Full Text] [Related]
6. Acute neuroleptic stimulates DOPA decarboxylase in porcine brain in vivo.
Danielsen EH; Smith D; Hermansen F; Gjedde A; Cumming P
Synapse; 2001 Aug; 41(2):172-5. PubMed ID: 11400183
[TBL] [Abstract][Full Text] [Related]
7. Modeling of fluorine-18-6-fluoro-L-Dopa in humans.
Wahl L; Nahmias C
J Nucl Med; 1996 Mar; 37(3):432-7. PubMed ID: 8772639
[TBL] [Abstract][Full Text] [Related]
8. The localization and functional contribution of striatal aromatic L-amino acid decarboxylase to L-3,4-dihydroxyphenylalanine decarboxylation in rodent parkinsonian models.
Nakamura K; Ahmed M; Barr E; Leiden JM; Kang UJ
Cell Transplant; 2000; 9(5):567-76. PubMed ID: 11144954
[TBL] [Abstract][Full Text] [Related]
9. Dopa decarboxylase activity of the living human brain.
Gjedde A; Reith J; Dyve S; Léger G; Guttman M; Diksic M; Evans A; Kuwabara H
Proc Natl Acad Sci U S A; 1991 Apr; 88(7):2721-5. PubMed ID: 1688340
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease.
Ishikawa T; Dhawan V; Chaly T; Margouleff C; Robeson W; Dahl JR; Mandel F; Spetsieris P; Eidelberg D
J Nucl Med; 1996 Feb; 37(2):216-22. PubMed ID: 8667047
[TBL] [Abstract][Full Text] [Related]
11. Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine.
Deep P; Dagher A; Sadikot A; Gjedde A; Cumming P
Synapse; 1999 Dec; 34(4):313-8. PubMed ID: 10529725
[TBL] [Abstract][Full Text] [Related]
12. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET.
Brooks DJ; Salmon EP; Mathias CJ; Quinn N; Leenders KL; Bannister R; Marsden CD; Frackowiak RS
Brain; 1990 Oct; 113 ( Pt 5)():1539-52. PubMed ID: 2123119
[TBL] [Abstract][Full Text] [Related]
13. Striatal kinetics of [11C]-(+)-nomifensine and 6-[18F]fluoro-L-dopa in Parkinson's disease measured with positron emission tomography.
Tedroff J; Aquilonius SM; Laihinen A; Rinne U; Hartvig P; Anderson J; Lundqvist H; Haaparanta M; Solin O; Antoni G
Acta Neurol Scand; 1990 Jan; 81(1):24-30. PubMed ID: 2330812
[TBL] [Abstract][Full Text] [Related]
14. The neurochemistry of Parkinson's disease: effect of L-dopa therapy.
Lloyd KG; Davidson L; Hornykiewicz O
J Pharmacol Exp Ther; 1975 Dec; 195(3):453-64. PubMed ID: 489
[TBL] [Abstract][Full Text] [Related]
15. Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naïve parkinsonism. Diagnostic implications of the D2 receptor status.
Sawle GV; Playford ED; Brooks DJ; Quinn N; Frackowiak RS
Brain; 1993 Aug; 116 ( Pt 4)():853-67. PubMed ID: 8353712
[TBL] [Abstract][Full Text] [Related]
16. Seasonality of striatal dopamine synthesis capacity in Parkinson's disease.
Kaasinen V; Jokinen P; Joutsa J; Eskola O; Rinne JO
Neurosci Lett; 2012 Nov; 530(1):80-4. PubMed ID: 23041046
[TBL] [Abstract][Full Text] [Related]
17. L-dihydroxyphenylalanine and its decarboxylase: new ideas on their neuroregulatory roles.
Opacka-Juffry J; Brooks DJ
Mov Disord; 1995 May; 10(3):241-9. PubMed ID: 7651438
[TBL] [Abstract][Full Text] [Related]
18. Cerebral uptake and utilization of therapeutic [beta-11C]-L-DOPA in Parkinson's disease measured by positron emission tomography. Relations to motor response.
Tedroff J; Aquilonius SM; Hartvig P; Bredberg E; Bjurling P; Långström B
Acta Neurol Scand; 1992 Feb; 85(2):95-102. PubMed ID: 1574995
[TBL] [Abstract][Full Text] [Related]
19. Dopa-decarboxylation in the striata of rats with unilateral substantia nigra lesions.
Kang UJ; Park DH; Wessel T; Baker H; Joh TH
Neurosci Lett; 1992 Nov; 147(1):53-7. PubMed ID: 1480324
[TBL] [Abstract][Full Text] [Related]
20. Parkinson's disease: activity of L-dopa decarboxylase in discrete brain regions.
Lloyd K; Hornykiewicz O
Science; 1970 Dec; 170(3963):1212-3. PubMed ID: 5478194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
